AstraZeneca AZN announced that it has entered into a definitive agreement to acquire EsoBiotec for developing in vivo cell ...

MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity ...

AstraZeneca has successfully completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell ...

AstraZeneca completes acquisition of biotech company, EsoBiotec: Cambridge, UK Wednesday, May 21, 2025, 09:00 Hrs [IST] AstraZeneca announced the successful completion of the acqu ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

British drug major AstraZeneca said on Monday it has entered into a definitive agreement to acquire EsoBiotec, a Belgian biotech company, for up to $1 billion on a cash and debt-free basis.

AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical ...

Initial clinical data from this trial are expected to be released in the second half of 2025,” said EsoBiotec Chief Scientific Officer Philippe Parone, PhD. “At ASGCT, we will present the ...